Acadia Healthcare Slashes 2025 Guidance Amid Soaring Liability Costs
Acadia Healthcare (ACHC) cuts 2025 earnings guidance by $49M as professional liability expenses skyrocket 115% year-over-year, signaling mounting legal troubles.
/ 909 items
#Healthcare↓
Raymond James Starts Coverage of Aardvark Therapeutics With Strong Buy Rating
Raymond James initiates Aardvark Therapeutics with a Strong Buy and a $47 price target, highlighting strong Phase 2 data for ARD-101 and unmet needs in hyperphagia treatment.
FDA Grants Breakthrough Therapy Status to Arrowhead’s Plozasiran for Severe High Triglycerides
Arrowhead Pharmaceuticals received FDA Breakthrough Therapy designation for plozasiran, a promising treatment aimed at lowering dangerously high triglyceride levels in adults with severe hypertriglyceridemia.
FDA Fast-Tracks New Treatment for Chronic Nerve Pain
Sangamo Therapeutics (SGMO) receives FDA Fast Track designation for ST-503, a promising non-opioid treatment for small fiber neuropathy causing chronic pain.
Jasper Therapeutics Stock Jumps on Positive Asthma Drug Results
Jasper Therapeutics (JSPR) shares rise 60% after experimental drug briquilimab shows promising results in early-stage asthma study, improving lung function and reducing inflammation.
TD Cowen Starts Coverage on C4 Therapeutics with a Buy Rating
TD Cowen initiates C4 Therapeutics with a Buy rating, highlighting its strong clinical validation in targeted protein degradation and the potential of Cemsi as a "backbone therapy" for multiple myeloma.